Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00086164 · ClinicalTrials.gov registry record · Phase 1
Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis
A Phase 1 study, sponsored by Anesiva.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00086164 is a Phase 1 study that was terminated before completion, run by Anesiva.
The verdict
NCT00086164, a Phase 1 study, was terminated before completion, sponsored by Anesiva.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
The purpose of this study is to determine the effect of recipient vein pretreatment of edifoligide (E2F Decoy), compared to placebo, on graft/recipient vein stenosis in polytetrafluoroethylene (PTFE) vascular access grafts placed for hemodialysis at 6 months after enrollment.
Interventions
- DRUG edifoligide (E2F Decoy)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00086164
The ClinicalTrials.gov registry entry for NCT00086164 describes a study currently listed as terminated, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Anesiva, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which edifoligide (E2F Decoy) is the first listed.
NCT00086164 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00086164 about?
NCT00086164 is a clinical study titled "Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis". The purpose of this study is to determine the effect of recipient vein pretreatment of edifoligide (E2F Decoy), compared to placebo, on graft/recipient vein stenosis in polytetrafluoroethylene (PTFE) vascular access grafts placed for hemodialysis at 6 months after enrollment.
What is the current status of trial NCT00086164?
This trial is currently terminated. It is a Phase 1 study. The study started on 2004-05.
What interventions are being tested in trial NCT00086164?
The interventions under investigation include: edifoligide (E2F Decoy) (DRUG).
Who is sponsoring clinical trial NCT00086164?
This trial is sponsored by Anesiva, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.